Skip to content
Search

Latest Stories

DHSC issues SSPs for Estraderm MX 25mcg and 100mcg patches

The Department of Health and Social Care (DHSC) has issued two new Serious Shortage Protocols (SSPs) for Estraderm MX 25mcg and 100mcg patches.

Effective from 8 September 2022, SSP035 and SSP036 provide that for every Estraderm MX 25mcg or 100mcg patch originally prescribed, one Evorel 25mcg patch or 100mcg patch must be supplied, respectively. Both SSPs are currently set to expire on 16 September 2022.


SSP035 for Estraderm MX® 25mcg patches

For prescriptions (NHS or private) requesting:Supply permitted under SSP035:
Estraderm MX® 25mcg patchesEvorel® 25mcg patches

SSP036 for Estraderm MX® 100mcg patches

For prescriptions (NHS or private) requesting:Supply permitted under SSP036:
Estraderm MX® 100mcg patchesEvorel® 100mcg patches

Both SSPs, authorised by the secretary of state for health, have been developed by clinicians and provides pharmacists with procedures to follow in providing either of these suitable alternative products to help reduce the number of patients having to return to their prescriber for a replacement prescription.

DHSC informed that there are no SSPs in place for Estraderm MX 50mcg patches and 75mcg patches – these strengths are not affected by supply disruptions and should continue to be dispensed in accordance with the prescriptions

“The SSP035 and SSP036 only allow substitution of Estraderm MX 25 or 100 patches with Evorel 25 or 100 patches, respectively.”

DHSC said: “The SSPs do not allow pharmacists to double up strengths for example, pharmacists cannot supply 2 x Estraderm MX 50 patches against a prescription ordering 1 x Estraderm MX 100 patches. The supervising pharmacist should ensure that the patient’s prescriber is notified when supplying a patient in accordance with these SSPs.”

“The supervising pharmacist, using their professional judgement determines that swapping the patient to a different brand of a patch would not be suitable for the patient.”

Pharmacists are required to read and comply with the requirements outlined within the individual SSP as published on the NHSBSA website for SSP035: Estraderm MX 25mcg patches and SSP036: Estraderm MX 100mcg patches.

DHSC said: “Reimbursement is for the medicine supplied in accordance with the SSP and not the originally prescribed medicine i.e. in this instance contractors will be reimbursed the reimbursement price for either Evorel 25mcg patches or 100mcg patches. The reimbursement price will account for VAT payment. Supply in accordance with the SSP will result in the following fees being paid to the contractor: One Single Activity fee (currently £1.27); One SSP fee (£5.35).”

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less